HIV

Going viral? J&J tries to spark a Twitterstorm for the latest data on its HIV med
Going viral? J&J tries to spark a Twitterstorm for the latest data on its HIV med
Endpoints
JNJ
HIV
Symtuza
social media
twitter
Flag link:
GSK wins U.S. nod for two-drug HIV combination
GSK wins U.S. nod for two-drug HIV combination
Yahoo/Reuters
GSK
FDA
HIV
Dovato
Flag link:
Gilead sees Descovy as successor to Truvada for HIV PrEP
Gilead sees Descovy as successor to Truvada for HIV PrEP
BioCentury
Gilead Sciences
Descovy
Truvada
HIV
PrEP
Flag link:
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
Pharmaceutical Business Review
ViiV Healthcare
Dolutegravir
rilpivirine
JNJ
Janssen
HIV
Flag link:
Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%
Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%
Motley Fool
Gilead Sciences
GS-6207
HIV
Flag link:
Gilead raises prices on top-selling HIV treatments
Gilead raises prices on top-selling HIV treatments
Biopharma Dive
Gilead Sciences
drug pricing
HIV
Flag link:
Gilead shares early clinical data on HIV capsid inhibitor
Gilead shares early clinical data on HIV capsid inhibitor
Fierce Biotech
Gilead Sciences
HIV
GS-6207
clinical trials
Flag link:
Monthly shots control HIV as well as daily pills in two big studies
Monthly shots control HIV as well as daily pills in two big studies
Stat
HIV
AIDS
JNJ
Janssen
ViiV Healthcare
cabotegravir
Edurant
Flag link:
Gilead scores key HIV data as Descovy proves non-inferior to Truvada
Gilead scores key HIV data as Descovy proves non-inferior to Truvada
BioPharma Dive
Gilead Sciences
HIV
Descovy
Truvada
clinical trials
Flag link:
Trump's HIV pledge comes as Gilead pumps cash into Truvada for PrEP
Trump's HIV pledge comes as Gilead pumps cash into Truvada for PrEP
Fierce Pharma
Gilead Sciences
HIV
Descovy
PrEP
Donald Trump
Flag link:
How to stop a lack of diversity undermining clinical trial data
How to stop a lack of diversity undermining clinical trial data
Financial Times
clinical trials
race
ethnicity
HIV
hypertension
cancer
Flag link:
7 Things to Expect for Gilead Sciences in 2019
7 Things to Expect for Gilead Sciences in 2019
Motley Fool
Gilead Sciences
JPMHC 2019
HIV
hepatitis C
M&A
Daniel O'Day
Flag link:
Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment
Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment
Biopharma Dive
GSK
ViiV Healthcare
HIV
Flag link:
ViiV Healthcare’s HIV-1 drug fostemsavir succeeds in phase 3 trial
ViiV Healthcare’s HIV-1 drug fostemsavir succeeds in phase 3 trial
Pharmaceutical Business Review
ViiV Healthcare
HIV
clinical trials
fostemsavir
Flag link:
Long-lasting HIV injection is a step closer after second GSK study
Long-lasting HIV injection is a step closer after second GSK study
Reuters
vaccines
GSK
HIV
cabotegravir
rilpivirine
Flag link:
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
CP Wire
Janssen
JNJ
Symtuza
HIV
Flag link:
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
Janssen
JNJ
Symtuza
HIV
Flag link:
Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?
Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?
Fierce Pharma
Gilead Sciences
HIV
Flag link:
Inovio touts intradermal delivery of HIV vaccine
Inovio touts intradermal delivery of HIV vaccine
Drug Delivery Business News
Invovio
HIV
vaccines
Pennvax-GP
Flag link:
US filing for ViiV’s two-drug, single pill HIV treatment
US filing for ViiV’s two-drug, single pill HIV treatment
Pharma Times
ViiV
FDA
HIV
dolutegravir/lamivudine
Flag link:

Pages